Workshop C: To What Extent Does TDP-43 Underlie ALS Pathology? Evaluating Novel Target Discovery & Validation to Address the Breadth of ALS Pathology
Time: 1:00 pm
day: Pre Conference Day PM
Details:
This workshop will delve into TDP-43’s role as a key driver of ALS pathology and explore broader mechanisms contributing to disease heterogeneity. Attendees will critically assess TDP-43 as a therapeutic target, how well TDP-43 accounts for all ALS pathology in sporadic ALS, identify other pathological drivers such as neuroinflammation and metabolic dysfunction, and refine preclinical strategies to validate novel targets.
The discussion will address the challenges of model selection, biomarker development, and the integration of TDP-43-targeted therapies into a multifaceted ALS treatment landscape.
- Evaluate TDP-43’s role in ALS pathology and its interaction with non-neuronal mechanisms, including neuroinflammation, mitochondrial dysfunction, and lipid metabolism
- Explore the utility of TDP-43 biomarkers and preclinical models in the context of target validation and preclinical development of novel drug mechanisms beyond TDP-43
- Discuss the positioning of TDP-43-targeted therapies within a broader ALS treatment landscape to address disease heterogeneity
- Refine preclinical strategies for better target validation and enhanced predictability of therapeutic efficacy in humans.
